
    
      This study is an open-label single-arm study to treat patients with refractory metastatic
      colorectal cancer and non-small cell lung cancer with liver metastasis. Patients' metastatic
      liver lesions will be treated with Trans-arterial Tirapazamine Embolization (TATE) for
      maximal tumor debulking along with IV injection of Pembrolizumab every three weeks until
      disease progression or maximally two years.
    
  